SMMT Summit Therapeutics Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:48
Aug 26
Aug 26
Premarket movers report shows mixed stock reactions to earnings and guidance.
Premarket movers report shows mixed stock reactions to earnings and guidance, with Nvidia and Mag 7 mostly higher ahead of Wednesday's earnings, while several companies like Intuit, Kohl's, and Zoom fall on weak forecasts and others like Photronics and Semtech rise on beats.
11:58
Aug 25
Aug 25
Raymond James upgrades AMD to Strong Buy with a raised price target.
Raymond James upgrades AMD to Strong Buy with a raised price target, while multiple other analysts issue upgrades and downgrades across various stocks including DT, SMMT, BFH, FLNC, FOUR, MRNA, CAPR, RLI, NTR, KLAR, PAY, DQ, FIVE, and FIS.
12:32
Aug 17
Aug 17
Notes Q2 aggregate fund value decrease
Notes the stock saw one of the largest aggregate value decreases across 93 funds in Q2 13F filings.
MED
14:00
Aug 04
Aug 04
Comparisons to ivonescimab, which is partnered by Summit, implicitly benchmark Pfizer's drug against Summit's key asset.
HIGH
23:56
Aug 03
Aug 03
Summit Therapeutics speculative biotech with insider buying.
Summit Therapeutics has heavy insider buying ($50M by co-CEO, $5M by management), is awaiting FDA approval with trial results better than an existing drug, and can be treated as a speculative buy for risk-tolerant investors.
LOW
11:56
Jun 01
Jun 01
Pre-market movers report highlights Nvidia and Microsoft unveiling AI superchip for PCs.
Pre-market movers report highlights Nvidia and Microsoft unveiling AI superchip for PCs, causing chip competitors to fall and partners to gain, along with other corporate news including Berkshire Hathaway's acquisition of TMHC and FedEx completing its spin-off.
05:36
Jan 16
Jan 16
Akeso drug approval odds look good.
Akeso's PD-1/VEGF bispecific ivonescimab, partnered with Summit Therapeutics, has good FDA approval odds based on four successful Phase III studies and consistent safety/efficacy data. The company sees multiple 2026 catalysts, including potential US approval and additional indications, plus pipeline optionality in bispecific ADCs, immunology, and Alzheimer's.
HIGH
About SMMT Investor Commentary
Across the available history and selected sources, Buzzberg tracks SMMT (Summit Therapeutics) across 7 sources: 2 bullish vs 0 bearish calls from 7 authors. Historical directional balance: 29% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 7 total trade ideas tracked. Latest voices: zerohedge, DeItaone, seedy19tron.